Tag: heart disease

The Centers for Medicare & Medicaid Services (CMS) officially released the Calendar Year (CY) 2027 Medicare Physician Fee Schedule (MPFS) proposed rule on July 14, signaling the start of a critical period for federal healthcare reimbursement policy and physician advocacy. This annual regulatory release outlines the proposed payment rates, quality reporting requirements, and policy changes…

The Clinical Intersection of Cushing’s Syndrome and Metabolic Disease Endogenous Cushing’s syndrome is a rare but devastating endocrine disorder characterized by the chronic overproduction of cortisol by the adrenal glands. This hypercortisolism is typically driven by a pituitary tumor (Cushing’s disease) or an adrenal tumor. Cortisol, often referred to as the "stress hormone," plays a…

The global healthcare landscape is currently grappling with a dual epidemic: a surge in type 2 diabetes and a rising prevalence of age-related metabolic decline in men. New research presented at the ENDO conference by Gary Wittert, MBBch, MD, of the University of Adelaide, has provided critical insights into how testosterone therapy might serve as…

Following the conclusion of the ENDO 2026 annual meeting in Chicago, the Endocrine Society has officially pivoted its focus toward a robust schedule of autumn programming designed to bridge the gap between foundational laboratory research and frontline clinical application. This upcoming slate of events, ranging from high-level scientific summits in Europe to intensive board preparation…

The healthcare landscape is currently witnessing a paradigm shift where artificial intelligence (AI) is transitioning from a high-tech novelty to a fundamental clinical necessity. This evolution was the central focus of a high-profile session at ENDO 2026, the annual meeting of the Endocrine Society, held in mid-June. Titled "Artificial Intelligence in Endocrinology: Practical Uses, Lessons…

The medical landscape for patients diagnosed with acromegaly has undergone a radical transformation over the last several decades, according to a comprehensive review recently published in The Journal of Clinical Endocrinology & Metabolism. The research, led by Daniela Esposito and Gudmundur Johannsson from the Sahlgrenska Academy at the University of Gothenburg, highlights a significant reduction…

Ascendis Pharma A/S, a biopharmaceutical leader dedicated to improving patients’ lives through its proprietary TransCon technology platform, recently announced a comprehensive update regarding its clinical programs for achondroplasia. On August 6, the company released significant 78-week data from its Phase 2 COACH trial, which evaluates a combination therapy of TransCon CNP (navepegritide) and TransCon hGH…

The announcement of the 2026 Laureate Awards by the Endocrine Society marks a significant milestone in the field of hormonal research and clinical practice, highlighting individuals who have demonstrated a lifetime of dedication to the advancement of endocrine science. Among the distinguished honorees, Dr. Martin Reincke stands out for his dual contributions as a high-level…

Lila Dabill, a doctoral candidate at Washington University in St. Louis, has been named the Basic Science winner of the 2026 Rising Star Power Talks, a premier research communication competition held during the Endocrine Society’s annual ENDO conference. Dabill’s research, conducted within the laboratory of Dr. Erica Scheller, investigates the pivotal role of the NADase…

The landscape of metabolic medicine shifted significantly on August 18 as Amylyx Pharmaceuticals, Inc. unveiled the topline results from its pivotal Phase 3 LUCIDITY clinical trial. The study, which evaluated the efficacy and safety of avexitide in patients suffering from post-bariatric hypoglycemia (PBH), met its primary endpoint with high statistical significance. Avexitide, an investigational, first-in-class…